Regeneron's Phase 3 trial testing fianlimab (LAG-3 inhibitor) combined with cemiplimab (PD-1 inhibitor) as first-line treatment for unresectable or metastatic melanoma did not achieve statistical significance for its primary endpoint of improved progression-free survival (PFS) compared to pembrolizumab alone. However, the high-dose combination showed a numeric improvement of 5.1 months in median PFS. No new safety concerns were reported. A separate Phase 3 trial comparing this high-dose combination to Opdualag is ongoing, with full trial results to be presented at a future medical meeting.
At the 2026 Regeneron International Science and Engineering Fair, over $7 million in awards were given to more than 1,700 young STEM students from 67+ countries. Hikaru Kuribayashi, 17, won the top $100,000 prize for his simulation program predicting...
The 2026 Regeneron International Science and Engineering Fair awarded more than $7 million to over 1,700 young STEM finalists from 67+ countries. Hikaru Kuribayashi won the top $100,000 George D. Yancopoulos Innovator Award for creating a simulation ...
At the Bank of America Healthcare Conference 2026, Regeneron Pharmaceuticals announced a new agreement granting them tariff relief and exemption from future US government pricing mandates through January 2029. This deal applies only to products wholl...
